眼结核:诊断与治疗管理的立场文件

L. Figueira , S. Fonseca , I. Ladeira , R. Duarte
{"title":"眼结核:诊断与治疗管理的立场文件","authors":"L. Figueira ,&nbsp;S. Fonseca ,&nbsp;I. Ladeira ,&nbsp;R. Duarte","doi":"10.1016/j.rppnen.2016.10.004","DOIUrl":null,"url":null,"abstract":"<div><p>Delay in diagnosis or treatment of ocular tuberculosis can result in loss of vision. However, due to the fact that early diagnosis is rarely achieved, there are still a broad variety of diagnostic and treatment approaches.</p><p>Our aim was to reach a consensus on the management of diagnosis and treatment of ocular tuberculosis.</p></div><div><h3>Methods</h3><p>Critical appraisal of the literature and expert opinion on diagnosis and treatment of ocular tuberculosis.</p></div><div><h3>Results and conclusion</h3><p>The currently recommended method for ocular TB diagnosis is screening for tuberculosis in any uveitis of unknown etiology, recurrent or not responding to conventional therapy; in ocular findings highly suggestive of ocular TB and before immunosuppression (particularly biologic agents). TB screening in these cases includes tuberculosis skin testing and interferon gamma testing, along with complete medical history, ophthalmologic evaluation and chest imaging. Positively screened patients should be treated for active tuberculosis with 4 drugs (isoniazid, rifampicin, pyrazinamide and ethambutol) for 6–9 months. Patients should be reviewed at the end of the initiation phase (two months) and at the end of the overall treatment (6–9 months).</p></div>","PeriodicalId":101122,"journal":{"name":"Revista Portuguesa de Pneumologia (English Edition)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rppnen.2016.10.004","citationCount":"32","resultStr":"{\"title\":\"Ocular tuberculosis: Position paper on diagnosis and treatment management\",\"authors\":\"L. Figueira ,&nbsp;S. Fonseca ,&nbsp;I. Ladeira ,&nbsp;R. Duarte\",\"doi\":\"10.1016/j.rppnen.2016.10.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Delay in diagnosis or treatment of ocular tuberculosis can result in loss of vision. However, due to the fact that early diagnosis is rarely achieved, there are still a broad variety of diagnostic and treatment approaches.</p><p>Our aim was to reach a consensus on the management of diagnosis and treatment of ocular tuberculosis.</p></div><div><h3>Methods</h3><p>Critical appraisal of the literature and expert opinion on diagnosis and treatment of ocular tuberculosis.</p></div><div><h3>Results and conclusion</h3><p>The currently recommended method for ocular TB diagnosis is screening for tuberculosis in any uveitis of unknown etiology, recurrent or not responding to conventional therapy; in ocular findings highly suggestive of ocular TB and before immunosuppression (particularly biologic agents). TB screening in these cases includes tuberculosis skin testing and interferon gamma testing, along with complete medical history, ophthalmologic evaluation and chest imaging. Positively screened patients should be treated for active tuberculosis with 4 drugs (isoniazid, rifampicin, pyrazinamide and ethambutol) for 6–9 months. Patients should be reviewed at the end of the initiation phase (two months) and at the end of the overall treatment (6–9 months).</p></div>\",\"PeriodicalId\":101122,\"journal\":{\"name\":\"Revista Portuguesa de Pneumologia (English Edition)\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.rppnen.2016.10.004\",\"citationCount\":\"32\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Portuguesa de Pneumologia (English Edition)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2173511516301294\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Portuguesa de Pneumologia (English Edition)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2173511516301294","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 32

摘要

眼结核的诊断或治疗延误可导致视力丧失。然而,由于早期诊断很少实现,仍然有各种各样的诊断和治疗方法。我们的目的是就眼结核的诊断和治疗管理达成共识。方法对眼结核的诊断和治疗方面的文献和专家意见进行批判性评价。结果与结论目前推荐的眼结核诊断方法是对任何病因不明、复发或常规治疗无效的葡萄膜炎进行结核筛查;在免疫抑制(特别是生物制剂)之前,眼部表现高度提示眼部结核病。在这些病例中,结核病筛查包括结核病皮肤试验和干扰素γ试验,以及完整的病史、眼科评估和胸部成像。筛查阳性的患者应使用4种药物(异烟肼、利福平、吡嗪酰胺和乙胺丁醇)治疗活动性结核病6-9个月。患者应在起始期结束时(2个月)和整体治疗结束时(6-9个月)进行复查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Ocular tuberculosis: Position paper on diagnosis and treatment management

Delay in diagnosis or treatment of ocular tuberculosis can result in loss of vision. However, due to the fact that early diagnosis is rarely achieved, there are still a broad variety of diagnostic and treatment approaches.

Our aim was to reach a consensus on the management of diagnosis and treatment of ocular tuberculosis.

Methods

Critical appraisal of the literature and expert opinion on diagnosis and treatment of ocular tuberculosis.

Results and conclusion

The currently recommended method for ocular TB diagnosis is screening for tuberculosis in any uveitis of unknown etiology, recurrent or not responding to conventional therapy; in ocular findings highly suggestive of ocular TB and before immunosuppression (particularly biologic agents). TB screening in these cases includes tuberculosis skin testing and interferon gamma testing, along with complete medical history, ophthalmologic evaluation and chest imaging. Positively screened patients should be treated for active tuberculosis with 4 drugs (isoniazid, rifampicin, pyrazinamide and ethambutol) for 6–9 months. Patients should be reviewed at the end of the initiation phase (two months) and at the end of the overall treatment (6–9 months).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信